Pinterest Inc vs Regeneron Pharmaceuticals Inc — how do they compare? Pinterest Inc trades at $18.42 (market cap $11.41B), while Regeneron Pharmaceuticals Inc trades at $807.6 (market cap $83.43B). The key difference: Regeneron Pharmaceuticals Inc is far larger — about 7.3× Pinterest Inc's market cap, and Regeneron Pharmaceuticals Inc pays a 0.46% dividend while Pinterest Inc pays none. Which is the better fit depends on your goals.
| PINS | REGN | |
|---|---|---|
Market Cap | $11.41B | $83.43B |
Sector | Media | Health |
52-Week High | $36.49 | $852.03 |
52-Week Low | $15.42 | $555.51 |
Enterprise Value | $11.33B | $78.14B |
Dividend Yield | — | 0.46% |
Signals from Pluang's Aura AI — not financial advice
Pinterest (PINS) trades at $20.14, down 1.27% with bearish technical signals despite recent earnings beats. The company shows strong revenue growth from $2.8B in 2022 to $4.2B in 2025, though net income margin compressed to 5.46%. Recent CFO resignation and insider selling have weighed on sentiment, while analyst consensus remains bullish with a $28.69 price target representing 42% upside potential.
PINS offers significant upside based on analyst targets but faces near-term headwinds from leadership transition and competitive pressures. The stock's high P/E ratio of 59.24 requires continued execution on AI-driven growth initiatives. Key risks include market share competition and the company's ability to monetize international users effectively while managing rising infrastructure costs from the $4B AWS partnership.
Regeneron Pharmaceuticals (REGN) trades at $810.31, down 2.1% today, with strong fundamentals including 84.9% gross margins and consistent earnings beats. The stock shows bullish technical signals with support at $805 and resistance at $838, while analyst consensus remains strongly positive with 69% buy ratings. Recent news highlights multiple class action lawsuits related to clinical trial disclosures, creating near-term sentiment headwinds despite solid financial performance.
Outlook remains cautiously optimistic given strong profitability and analyst support, though legal risks and clinical trial uncertainties present challenges. The stock trades above consensus price target of $756.82, suggesting limited near-term upside potential despite robust fundamentals and institutional confidence.
Trailing returns across standard periods
Latest headlines on both assets
Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including Eylea, approved for wet age-related macular degeneration and other eye diseases
Read more on REGN →